CN101072557A - Ppar激动剂用于治疗充血性心力衰竭的用途 - Google Patents

Ppar激动剂用于治疗充血性心力衰竭的用途 Download PDF

Info

Publication number
CN101072557A
CN101072557A CNA2005800416904A CN200580041690A CN101072557A CN 101072557 A CN101072557 A CN 101072557A CN A2005800416904 A CNA2005800416904 A CN A2005800416904A CN 200580041690 A CN200580041690 A CN 200580041690A CN 101072557 A CN101072557 A CN 101072557A
Authority
CN
China
Prior art keywords
ppar
chemical compound
heart failure
formula
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800416904A
Other languages
English (en)
Chinese (zh)
Inventor
W·林茨
S·沙费尔
E·法尔克
H-L·舍费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN101072557A publication Critical patent/CN101072557A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2005800416904A 2004-12-17 2005-12-06 Ppar激动剂用于治疗充血性心力衰竭的用途 Pending CN101072557A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure
EP04029946.3 2004-12-17

Publications (1)

Publication Number Publication Date
CN101072557A true CN101072557A (zh) 2007-11-14

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800416904A Pending CN101072557A (zh) 2004-12-17 2005-12-06 Ppar激动剂用于治疗充血性心力衰竭的用途

Country Status (16)

Country Link
US (1) US7601863B2 (enExample)
EP (2) EP1671633A1 (enExample)
JP (1) JP2008524129A (enExample)
KR (1) KR20070086332A (enExample)
CN (1) CN101072557A (enExample)
AR (1) AR051723A1 (enExample)
AT (1) ATE498400T1 (enExample)
AU (1) AU2005315920A1 (enExample)
BR (1) BRPI0519661A2 (enExample)
CA (1) CA2590391A1 (enExample)
DE (1) DE602005026443D1 (enExample)
IL (1) IL183810A0 (enExample)
MX (1) MX2007006678A (enExample)
MY (1) MY141010A (enExample)
TW (1) TW200635584A (enExample)
WO (1) WO2006063715A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843857A (zh) * 2016-10-05 2019-06-04 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100556A (et) * 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
UA76773C2 (uk) 2001-08-31 2006-09-15 Санофі-Авентіс Дойчланд Гмбх Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843857A (zh) * 2016-10-05 2019-06-04 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
US11530192B2 (en) 2016-10-05 2022-12-20 Mitobridge, Inc. Crystalline and salt forms of PPAR agonist compounds
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
US11912681B2 (en) 2016-10-05 2024-02-27 Mitobridge, Inc. Crystalline and salt forms of PPAR agonist compounds

Also Published As

Publication number Publication date
CA2590391A1 (en) 2006-06-22
EP1827425B1 (en) 2011-02-16
JP2008524129A (ja) 2008-07-10
AU2005315920A1 (en) 2006-06-22
WO2006063715A1 (en) 2006-06-22
US7601863B2 (en) 2009-10-13
MX2007006678A (es) 2007-08-14
KR20070086332A (ko) 2007-08-27
US20080039512A1 (en) 2008-02-14
EP1827425A1 (en) 2007-09-05
MY141010A (en) 2010-02-25
TW200635584A (en) 2006-10-16
AR051723A1 (es) 2007-01-31
IL183810A0 (en) 2007-10-31
ATE498400T1 (de) 2011-03-15
BRPI0519661A2 (pt) 2009-03-03
DE602005026443D1 (de) 2011-03-31
EP1671633A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
DE69830069T3 (de) Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
WO2007138362A1 (en) Use of gpcr agonists to delay progression of diabetes
AU2012290987B2 (en) Left ventricular diastolic function improving agent
CN104644619A (zh) 改善药物中具有脒官能团的活性物质的生物利用度
US20230218563A1 (en) Methods for treating or preventing chronic kidney disease
CN101072557A (zh) Ppar激动剂用于治疗充血性心力衰竭的用途
CA3137138A1 (en) Methods of treating hypertension with activators of tie-2
CN115671105B (zh) Ly2922470在制备预防或治疗肾脏疾病药物中的应用
JP4096122B2 (ja) 心臓線維芽細胞の増殖および心線維症を抑制する方法
SK19332001A3 (sk) Použitie antagonistov kortizolu v liečení srdcového zlyhania
US9604894B2 (en) Compounds from antrodia camphorate and their use in treatment of diabetes mellitus
WO2023009710A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
CN113398114A (zh) 3,7,8,4’-四羟基黄酮在制备抗心血管疾病药物中的应用
US20240091175A1 (en) Methods of controlling myocardial blood flow
KR20030087051A (ko) 아릴에텐술폰아미드 유도체의 신규한 용도
KR101598380B1 (ko) 당뇨병 또는 당뇨 합병증의 예방 또는 치료용 조성물
Bresslert et al. The Effect of B-Adrenergic Receptor Blocking Agents on Drug-Induced Insulin Secretion
TWI462923B (zh) Ｋｍｕｐ－３之心肌梗塞疾患用途
JPH1180014A (ja) アガリクス・ブラゼイエキスを有効成分として含有する血糖降下剤
CN101474174B (zh) N-[2-甲基-1-(吡咯烷-1-碳酰基)-丙基]-3-苯基丙酰胺在制药中的应用
WO2015134357A1 (en) Modulators of insulin receptor
JPS60226811A (ja) 抗動脈硬化剤
CN109394740A (zh) 异甘草素、药物组合物及其在制备治疗糖尿病心肌病药物中的应用
Shimamura et al. The effect of intermittent administration of sustained release isosorbide dinitrate (sr-ISDN) in rats with volume overload heart

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111346

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20071114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1111346

Country of ref document: HK